脑实质直接给予表达CLN2的rh.10腺相关病毒减缓晚婴型Batten病进展
这项非随机试验评估脑实质内给予AAVrh.10hCLN2对晚婴型Batten病(CLN2病)的效果,治疗组8例轻中度患儿与两套自然史队列比较18个月。治疗后脑脊液TPP1升高1.3至2.6倍,运动与语言功能下降速率分别减缓42.4%和47.5%,但仍需改进载体设计与递送策略以阻止疾病进展。
要点
- 脑实质内注射AAVrh.10hCLN2在轻中度CLN2病患儿中减缓运动与语言功能下降。
- 治疗组脑脊液TPP1升高1.3至2.6倍,7例中4例MRI灰质体积丢失变慢。
- 需改进载体设计与递送策略才能阻止疾病进展。
核心结论
- 脑实质内给予AAVrh.10hCLN2可减缓CLN2病患儿疾病进展,但不足以阻止进展。
研究设计与样本
- 非随机试验设两臂、观察18个月:治疗组8例轻中度CLN2病患儿,对照为Weill Cornell自然史队列12例患儿。
- 治疗组另与欧洲CLN2病自然史队列比较;另按单独方案对5例重度CLN2病患儿做安全性评估。
- 载体经6个颅孔直接注射至脑内12个位点,未使用免疫抑制。
主要发现
- 治疗后治疗组脑脊液TPP1升高1.3至2.6倍。
- 7例中4例MRI显示灰质体积丢失减慢。
- 与Weill Cornell自然史队列比,运动与语言功能下降速率分别减缓42.4%和47.5%(P < 0.04)。
- 与欧洲自然史队列比,运动与语言功能下降速率分别减缓42.4%和47.5%(P < 0.0001)。
- 治疗相关不良事件多为预期事件,无导致长期残疾者;系统性抗AAVrh.10免疫诱导轻微。
临床怎么用
- 该策略显示可减缓CLN2病进展,但当前载体设计与递送方式尚不能阻止疾病进展。
局限性
- 研究为非随机设计,治疗组与自然史队列比较存在非随机对照局限。
- 安全性评估在单独方案下进行,重度患儿样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Late infantile Batten disease (CLN2 disease) is an autosomal recessive, neurodegenerative lysosomal storage disease caused by mutations in the CLN2 gene encoding tripeptidyl peptidase 1 (TPP1). We tested intraparenchymal delivery of AAVrh.10hCLN2, a nonhuman serotype rh.10 adeno-associated virus vector encoding human CLN2, in a nonrandomized trial consisting of two arms assessed over 18 months: AAVrh.10hCLN2-treated cohort of 8 children with mild to moderate disease and an untreated, Weill Cornell natural history cohort consisting of 12 children. The treated cohort was also compared to an untreated European natural history cohort of CLN2 disease. The vector was administered through six burr holes directly to 12 sites in the brain without immunosuppression. In an additional safety assessment under a separate protocol, five children with severe CLN2 disease were treated with AAVrh.10hCLN2. The therapy was associated with a variety of expected adverse events, none causing long-term disability. Induction of systemic anti-AAVrh.10 immunity was mild. After therapy, the treated cohort had a 1.3- to 2.6-fold increase in cerebral spinal fluid TPP1. There was a slower loss of gray matter volume in four of seven children by MRI and a 42.4 and 47.5% reduction in the rate of decline of motor and language function, compared to Weill Cornell natural history cohort (P < 0.04) and European natural history cohort (P < 0.0001), respectively. Intraparenchymal brain administration of AAVrh.10hCLN2 slowed the progression of disease in children with CLN2 disease. However, improvements in vector design and delivery strategies will be necessary to halt disease progression using gene therapy.
引用
- Sondhi D, Kaminsky SM, Hackett NR, et al. Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. Sci Transl Med. 2020. PMID: 33268510. doi:10.1126/scitranslmed.abb5413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。